LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.

Early risk assessment of Down syndrome and other conditions

MaterniT 21 PLUS

Did you know that information on your baby’s health can be found in your own bloodstream?

The MaterniT® 21 PLUS test analyzes genetic information that enters your bloodstream from the placenta.

It screens for certain chromosomal abnormalities that could affect your baby’s health and development—such as trisomy 21 (Down syndrome) and sex chromosome aneuploidies (SCAs, abnormal numbers of X or Y chromosomes)—and can also detect if you’re having a boy or a girl.

A noninvasive blood test

There are many ways to get this genetic information, including methods such as serum screens and diagnostic procedures such as amniocentesis.

As a noninvasive prenatal test, MaterniT 21 PLUS is different from both. It has higher detection rates than serum screening,1 and requires only a blood sample from the mother; amniocentesis requires withdrawing fluid from around the developing baby.

MaterniT 21 PLUS

Accurate, easy-to-understand results

MaterniT 21 PLUS delivers answers in terms you can easily understand, with clear positive or negative results for well-known chromosomal abnormalities, such as trisomy 21 (Down syndrome), typically returned within five days.

Also, if you’re carrying twins, MaterniT 21 PLUS can detect common chromosomal abnormalities in your pregnancy as well.

Other testing options

In addition to NIPT, we offer: serum screening for Down syndrome and other conditions; carrier screening for disorders such as cystic fibrosis; diagnostic testing options for post-pregnancy or further confirmation of screening tests; and hereditary cancer screening.

If you’ve not had a test and have questions about costs or coverage, use our estimator.

If you have already had a test performed, we can help answer questions about results.

Ask questions about genetic testing options or results, or schedule an appointment.

Reference

  1. Committee on Practice Bulletins—Obstetrics, Committee on Genetics, and Society for Maternal-Fetal Medicine. Screening for fetal aneuploidy. Practice Bulletin No. 163. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2016; 127:e123–37.